FDA Not Convinced Columbia Lab's Gel has What it Takes
By Mari Serebrov
Thursday, January 19, 2012
Columbia Laboratories Inc.'s attempt to find a niche for its Prochieve progesterone gel to reduce the risk of preterm birth may have raised more questions than answers, at least as far as the FDA is concerned.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.